Topical medicaments comprising protamine and its derivatives
Aerosol compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a propellant. Specified propellants are dichlorodifluoromethane, difluoroethane, and trichlorofluoromethane. The compositions may contain one or more anti-inflammatory or analg...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | GLASER ERIC MICHAEL O'MEARA ROBERT ALLEN QUAIN MARSDEN RICHARD |
description | Aerosol compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a propellant. Specified propellants are dichlorodifluoromethane, difluoroethane, and trichlorofluoromethane. The compositions may contain one or more anti-inflammatory or analgesic substances, e.g. hydrocortisone, preservatives, oils, or emulsifying agents.ALSO:Pharmaceutical compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a topical vehicle. The compositions may contain one or more anti-inflammatory or analgesic substances e.g. hydrocortisone. The compositions may be in the form of ointments, lotions, creams, sticks, emulsions, powders, solutions, spray solutions, nasal spray solutions, aerosols, lozenges, paints for the nose, mouth and pharynx and rectal and vaginal suppositories. In aqueous preparations, the solubility in water of the protamine can be improved by the presence of formaldehyde-bisulphite or formaldehyde-sulphoxylate complex. The pH of the preparations should preferably be neutral or be within the range 4-7. The compositions may contain one or more preservatives and conventional excipients where necessary. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_GB1033737A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>GB1033737A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_GB1033737A3</originalsourceid><addsrcrecordid>eNrjZLAJyS_ITE7MUchNTQHSual5JcUKyfm5BUWZxZl56QoFRfklibmZeakKiXkpCplAyZTUosyyxJLMstRiHgbWtMSc4lReKM3NIO_mGuLsoZtakB-fWlyQmJyal1oS7-5kaGBsbG5s7mhMWAUAc48viA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Topical medicaments comprising protamine and its derivatives</title><source>esp@cenet</source><creator>GLASER ERIC MICHAEL ; O'MEARA ROBERT ALLEN QUAIN ; MARSDEN RICHARD</creator><creatorcontrib>GLASER ERIC MICHAEL ; O'MEARA ROBERT ALLEN QUAIN ; MARSDEN RICHARD</creatorcontrib><description>Aerosol compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a propellant. Specified propellants are dichlorodifluoromethane, difluoroethane, and trichlorofluoromethane. The compositions may contain one or more anti-inflammatory or analgesic substances, e.g. hydrocortisone, preservatives, oils, or emulsifying agents.ALSO:Pharmaceutical compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a topical vehicle. The compositions may contain one or more anti-inflammatory or analgesic substances e.g. hydrocortisone. The compositions may be in the form of ointments, lotions, creams, sticks, emulsions, powders, solutions, spray solutions, nasal spray solutions, aerosols, lozenges, paints for the nose, mouth and pharynx and rectal and vaginal suppositories. In aqueous preparations, the solubility in water of the protamine can be improved by the presence of formaldehyde-bisulphite or formaldehyde-sulphoxylate complex. The pH of the preparations should preferably be neutral or be within the range 4-7. The compositions may contain one or more preservatives and conventional excipients where necessary.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>1966</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19660622&DB=EPODOC&CC=GB&NR=1033737A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25544,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19660622&DB=EPODOC&CC=GB&NR=1033737A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GLASER ERIC MICHAEL</creatorcontrib><creatorcontrib>O'MEARA ROBERT ALLEN QUAIN</creatorcontrib><creatorcontrib>MARSDEN RICHARD</creatorcontrib><title>Topical medicaments comprising protamine and its derivatives</title><description>Aerosol compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a propellant. Specified propellants are dichlorodifluoromethane, difluoroethane, and trichlorofluoromethane. The compositions may contain one or more anti-inflammatory or analgesic substances, e.g. hydrocortisone, preservatives, oils, or emulsifying agents.ALSO:Pharmaceutical compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a topical vehicle. The compositions may contain one or more anti-inflammatory or analgesic substances e.g. hydrocortisone. The compositions may be in the form of ointments, lotions, creams, sticks, emulsions, powders, solutions, spray solutions, nasal spray solutions, aerosols, lozenges, paints for the nose, mouth and pharynx and rectal and vaginal suppositories. In aqueous preparations, the solubility in water of the protamine can be improved by the presence of formaldehyde-bisulphite or formaldehyde-sulphoxylate complex. The pH of the preparations should preferably be neutral or be within the range 4-7. The compositions may contain one or more preservatives and conventional excipients where necessary.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1966</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAJyS_ITE7MUchNTQHSual5JcUKyfm5BUWZxZl56QoFRfklibmZeakKiXkpCplAyZTUosyyxJLMstRiHgbWtMSc4lReKM3NIO_mGuLsoZtakB-fWlyQmJyal1oS7-5kaGBsbG5s7mhMWAUAc48viA</recordid><startdate>19660622</startdate><enddate>19660622</enddate><creator>GLASER ERIC MICHAEL</creator><creator>O'MEARA ROBERT ALLEN QUAIN</creator><creator>MARSDEN RICHARD</creator><scope>EVB</scope></search><sort><creationdate>19660622</creationdate><title>Topical medicaments comprising protamine and its derivatives</title><author>GLASER ERIC MICHAEL ; O'MEARA ROBERT ALLEN QUAIN ; MARSDEN RICHARD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_GB1033737A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1966</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>GLASER ERIC MICHAEL</creatorcontrib><creatorcontrib>O'MEARA ROBERT ALLEN QUAIN</creatorcontrib><creatorcontrib>MARSDEN RICHARD</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GLASER ERIC MICHAEL</au><au>O'MEARA ROBERT ALLEN QUAIN</au><au>MARSDEN RICHARD</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Topical medicaments comprising protamine and its derivatives</title><date>1966-06-22</date><risdate>1966</risdate><abstract>Aerosol compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a propellant. Specified propellants are dichlorodifluoromethane, difluoroethane, and trichlorofluoromethane. The compositions may contain one or more anti-inflammatory or analgesic substances, e.g. hydrocortisone, preservatives, oils, or emulsifying agents.ALSO:Pharmaceutical compositions for the treatment of skin cancer comprise protamine, or a physiologically-compatible salt thereof, and a topical vehicle. The compositions may contain one or more anti-inflammatory or analgesic substances e.g. hydrocortisone. The compositions may be in the form of ointments, lotions, creams, sticks, emulsions, powders, solutions, spray solutions, nasal spray solutions, aerosols, lozenges, paints for the nose, mouth and pharynx and rectal and vaginal suppositories. In aqueous preparations, the solubility in water of the protamine can be improved by the presence of formaldehyde-bisulphite or formaldehyde-sulphoxylate complex. The pH of the preparations should preferably be neutral or be within the range 4-7. The compositions may contain one or more preservatives and conventional excipients where necessary.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_GB1033737A |
source | esp@cenet |
subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
title | Topical medicaments comprising protamine and its derivatives |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A20%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GLASER%20ERIC%20MICHAEL&rft.date=1966-06-22&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EGB1033737A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |